1. Home
  2. LIAN

LIAN

LianBio

Logo LianBio

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-02-2024 10:34am EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications.

Founded: 2019 Country:
United States
United States
Employees: N/A City: PRINCETON
Market Cap: 37.6M IPO Year: 2021
Target Price: $5.33 AVG Volume (30 days): 925.0K
Analyst Decision: Hold Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.81 EPS Growth: N/A
52 Week Low/High: $0.27 - $4.99 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: